ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

L-PAM, Less Than Radical Surgery Results Holding Up, New Breast Cancer Studies Sought

September 12, 1975

Some Cancer Control Projects On Thin Ice As Board Eyes Funds For Others

January 29, 1982

NCCTG Plans To Conduct Phase II Study Of Brostallicin Plus Cisplatin For mTNBC

April 30, 2010

Funding Opportunities: NCI Request for Applications

April 28, 2000

CMS Looks At Coverage of Two Agents Approved on Surrogate Endpoints

March 21, 2003

Also: CALGB elects Schilsky to third term as chairman.

July 16, 2004